Open Access

AGTR1 rs3772622 gene polymorphism increase the risk of nonalcoholic fatty liver disease patients suffer coronary artery disease in Northern Chinese Han population

Lipids in Health and Disease201615:113

https://doi.org/10.1186/s12944-016-0279-3

Received: 16 April 2016

Accepted: 15 June 2016

Published: 24 June 2016

Abstract

Background

Cardiovascular disease (CAD) responsible and nonalcoholic fatty liver disease (NAFLD) are both metabolic diseases, and they are mostly influenced by genetic factors. The aim of our study is to evaluate the relationship between angiotensin II type-1 receptor (AGTR1) gene rs3772622 polymorphisms and the risk of developing coronary artery disease (CAD) in Chinese patients with NAFLD.

Methods

Genotype for AGTR1 rs3772622 in 574 NAFLD patients with CAD or 589 NAFLD patients without CAD, 332 CAD patients exclude NAFLD and 338 health control subjects were determined by sequencing and polymerase chain reaction analysis. Relevant statistical methods were employed to analyze the genotypes, alleles and the clinical date. Inter-group differences and associations were assessed statistically using t-tests and Chi square and logistic analyses. The relative risk of AGTR1 rs3772622 for NAFLD was estimated by logistic regression analysis.

Results

No significant difference in genotype and allele frequency of AGTR1 rs3772622 was found between the NAFLD without CAD population and the controls (P > 0.05). However, makeable difference was found when compared the CAD in patients with NAFLD and CAD free NAFLD patients (P < 0.001 OR = 2.09). Similarly, significant difference was found in AGTR1 rs3772622 genotype distribution between the groups of CAD patients and control (P = 0.046 OR = 1.71).

Conclusions

AGTR1 rs3772622 gene polymorphism was not associated with the risk of NAFLD, but could increase the risk of NAFLD patients suffering from CAD in the Chinese Han population. Deeply mechanisms underlying the association between AGTR1 rs3772622 gene polymorphism and the risk of CAD in NAFLD patients need more research.

Keywords

AGTR1 Polymorphism Genetic Non-alcoholic Fatty Liver Disease Coronary Artery Disease

Background

Nonalcoholic fatty liver disease (NAFLD) influenced by the incidence of Obesity has become one of the most common chronic liver disease and a primary health issue [1]. NAFLD is a metabolic disease without obvious alcohol intake, because of the abnormal metabolism making fat accumulated in the liver. On behalf of a spectrum of disease, NAFLD range from simple steatosis to steatohepatitis, and finally lead to cirrhosis [2, 3]. NAFLD can increased the risk of all-cause mortality, contributed by liver related deaths as well as non-liver related causes such as malignancy, diabetes and coronary artery disease (CAD) [4]. Epidemiological studies performed in United States and Japan showed that NAFLD can increased the risk of cardiovascular disease (CVD) and is a predictor of CVD independent of the presence of other metabolic syndrome risk factors, such as hypertension, diabetes, dyslipidaemia, insulin resistance (IR) and obesity [5, 6].

Angiotensin II type 1 receptor (AGTR1) gene has been implicated with susceptibility to NAFLD and was reported playing a fibrogenic role in NAFLD. Polymorphism of AGTR1 rs3772622 was reported to be associated with increased fibrosis score [7]. Furthermore, AGTR1 is an important receptor that controlling blood pressure and regulating cardiovascular homeostasis. It was reported that AGTR1 gene (A1166C) polymorphism was associated with hypertension and atherosclerotic stroke [811]. It was reasonable to speculate that AGTR1 may be one of the candidate genes in the susceptibility for NAFLD patients with CAD. However, the role of AGTR1 rs3772622 in atherosclerosis has not been elucidated.

This is the first report to investigate the association between AGTR1 rs3772622 and NAFLD patients with CAD.

Methods

Ethics statement

Our study was confirmed by the Ethical Committee of Qingdao Municipal Hospital (Qingdao, China), the reference number: 2015–01. And we prepared a written informed consent form for the participants to confirm that they were willing to participate. This study was carried out on the basis of the principles of the Declaration of Helsinki [12].

Study subjects

The controls were recruited from the Departments of Gastroenterology and Cardiology of Qingdao Municipal Hospital. All groups of participant were of Northern Han Chinese origin. NAFLD patients were diagnosed by B-type ultrasonography, The diagnosis of NAFLD was according to the standard clinical evaluation [13]. CAD was diagnosed by a percutaneous coronary angiogram, and the final diagnosis was determined by two skilled interventional cardiologists, diagnostic criteria for CAD is that not less than 50 % stenosis in at least one of the coronary arteries. The individuals in control group were confirmed as being normal by echocardiography and laboratory examinations at the identical hospital. Subjects should be excluded other liver diseases, such as nonalcoholic fatty hepatitis (NASH), the drug-induced liver disease, autoimmune liver disease, viral hepatitis, and the Weekly drinking > 140 g, other diseases such as cardiac disorders, concurrent major renal, infectious disease, diabetes mellitus, and malignant disease, and a history of medication. Study questionnaire was used to get the basic clinic pathological information (name, age, etc.).

To test our hypothesis, we finally selected a total of 1163 unrelated adult Chinese NAFLD patients of both genders [574 patients with CAD (292 females, 282 males, mean age 43.81 ± 7.58) and 589 patients without CAD (301 females, 288 males, mean age 45.06 ± 8.77)]. 332 unrelated adult Chinese CAD patients without NAFLD of both genders (168 females, 164 males, mean age 46.45 ± 9.68), and 338 health control of both genders (173 females, 165 males, mean age 43.85 ± 8.79). All subjects were of Northern Han Chinese origin, as described previously.

Clinical and laboratory assessments

Each of the subjects was fasted for 12 h before examination. For biochemical analyses, blood samples of all participants were determined for Triglyceride (TG), serum levels of total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT). The biochemical tests were analyzed by applying an automatic biochemistry analyzer (Hitachi P7600). Body weight and height were measured for calculate body mass index (BMI). According to a standard protocol of the 3-day baseline observation on each morning, three BP measurements can be obtained. The men who have a systolic BP 140 mmHg and/or diastolic BP 90 mmHg or use of antihypertensive medication can be diagnosed as hypertension.

Genotyping

Simples of peripheral blood were collected and genomic DNA was extracted by using the Genomic DNA Purification Kit (CWBIO, China), then stored at −20 °C until use. The AGTR1 SNP was genotyped using PCR analysis with the following primers for AGTR1 rs3772622 polymorphism: 5′ - CAGGAGCTCTGAGAGGAATGTTCAG - 3′ and 5′-TGGCAGATCAGCTGGGTTCATT-3′. The amplified reaction system and the PCR amplification profile progressed as previously described [14].

Statistical analysis

SPSS statistical software, version 20.0 (SPSS, Chicago, IL, USA) can be used to analyze data. Inspection level a = 0.05. Firstly, the quantitative data in the indexes were tested by t test, and the results were represented by the form of mean ± standard deviation (S.D.). Through counting DNA sequencing data, the genotype and allele frequencies can be estimated. The distinctions between studied groups were analyzed by Pearson’s χ2 test. Then, logistic regression analysis was used to measure the strength of the association between AGTR1 rs3772622 polymorphism and CAD, and it evaluated by the OR (95 % CI). At last, by comparing the OR values of the two groups with/without NAFLD, we can find the association between AGTR1 gene polymorphisms and coronary artery disease in patients with nonalcoholic fatty liver disease.

Results

Sample basic information

Table 1 presented the basic characteristics of this study population. There was no statistical significance in gender and age in each group (all p > 0.05). While, compared to the health control group, groups of NAFLD patients, with or without CAD (CAD+ NAFLD/CAD- NAFLD), and CAD patients without NAFLD (NAFLD- CAD) had increased serum ALT, AST, TG, TC, and LDL levels, BMI index, while the HDL levels decreased. (p1,2,3 < 0.001).
Table 1

Basic characteristics of this study population

Characteristics

Groups

P value

CAD+ NAFLD (n = 574)

CAD- NAFLD (n = 589)

NAFLD-CAD (n = 332)

Controls (n = 338)

P1

P2

P3

P4

Age (years)

43.81 ± 7.58

45.06 ± 8.77

46.45 ± 9.68

43.85 ± 8.79

0.996

0.921

0.884

0.912

Sex Female/male

292/282

301/288

168/164

173/165

0.927

0.981

0.880

0.934

Smoker, no. (%)

244 (42.5)

158 (26.8)

132 (39.6)

105 (31.3)

<0.001

<0.001

0.019

<0.001

Hypertension, no. (%)

279 (48.6)

225 (38.2)

147 (44.3)

71 (21.2)

<0.001

<0.001

<0.001

<0.001

ALT (U/L)

41.05 ± 8.50

40.69 ± 9.42

21.91 ± 5.90

19.15 ± 6.04

<0.001

<0.001

<0.001

0.487

AST (U/L)

42.67 ± 7.58

42.32 ± 8.12

22.11 ± 5.71

21.63 ± 5.82

<0.001

<0.001

0.035

0.451

GGT (U/L)

40.18 ± 8.42

40.08 ± 8.42

22.37 ± 5.35

19.43 ± 5.60

<0.001

<0.001

<0.001

0.839

TG (mmol/L)

2.49 ± 0.94

2.02 ± 0.82

1.41 ± 0.75

1.28 ± 0.70

<0.001

<0.001

0.027

<0.001

TC (mmol/L)

5.50 ± 1.01

4.72 ± 1.32

4.52 ± 1.22

4.04 ± 1.24

<0.001

<0.001

<0.001

<0.001

HDL (mmol/L)

1.10 ± 0.25

1.22 ± 0.31

1.34 ± 0.46

2.19 ± 0.64

<0.001

<0.001

<0.001

<0.001

LDL (mmol/L)

3.22 ± 0.62

2.96 ± 0.72

2.40 ± 0.57

2.54 ± 0.62

<0.001

<0.001

<0.001

<0.001

BMI (kg/m2)

26.88 ± 3.77

26.29 ± 4.03

26.18 ± 3.42

23.22 ± 2.69

<0.001

<0.001

<0.001

0.988

BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein. p1: CAD+ NAFLD vs. Control; p2: CAD-NAFLD vs. Control; p3: NAFLD-CAD vs. Control; p4: CAD+ NAFLD vs. CAD-NAFLD

Importantly, CAD+ NAFLD group patients had higher TG, TC, and LDL levels and lower HDL level than CAD- NAFLD group patients (p4 < 0.001).

AGTR1 rs3772622 genotype and allele distribution

The genotype and allele distribution were showed in Table 2, it indicated that there was no significant difference between CAD- NAFLD patients and control group (p > 0.05). As shown in Table 3, there was significant difference in genotypic and allelic distributions between the NAFLD patients with or without CAD (OR: 2.09, 95 % CI: 1.49-2.95, P < 0.001; OR: 1.83, 95 % CI: 1.39-2.41, P < 0.001 respectively). Furthermore, a considerable significant difference of genotype distribution were observed between CAD patients without NAFLD and health control people (OR: 1.71, 95 % CI: 1.002-2.860, P = 0.046), While there’s no significant difference of alleles distribution were observed from the above groups (OR: 1.04, 95 % CI: 0.77-1.41, P = 0.80).
Table 2

Distribution ofAGTR1 rs772622 polymorphisms in CAD-NAFLD and control groups

Groups

genotype

 

alleles

T/T

C/T

C/C

T

C

control

115 (34)

155 (45.9)

68 (20.1)

385 (56.9)

291 (43.1)

CAD-NAFLD

161 (27.3)

301 (51.1)

127 (21.6)

623 (52.4)

555 (46.4)

χ2

4.64

2.86

p value

0.098

0.091

Table 3

Distribution of AGTR1 rs772622 polymorphisms in these study groups

Genotype

CAD+ NAFLD N (%)

CAD-NAFLD N (%)

NAFLD-CAD N (%)

Controls N (%)

OR (95%CI)

P1

OR (95%CI)

P2

TT

168 (29.3)

259 (44.0)

147 (44.3)

153 (45.3)

    

CT

292 (50.9)

246 (41.8)

129 (38.9)

155 (45.8)

    

CC

114 (19.8)

84 (14.2)

56 (16.8)

30 (8.9)

2.09 (1.49-2.95)

<0.001

1.71 (1.02-2.86)

0.046

AlleleT

628 (54.7)

764 (64.9)

400 (60.2)

461 (68.2)

    

AlleleC

520 (45.3)

628 (54.7)

264 (39.8)

215 (31.8)

1.83 (1.39-2.41)

<0.001

1.04 (0.77-1.41)

0.80

P1: CAD-NAFLD vs CAD + NAFLD; P2: CAD + NAFLD- vs control

Discussion and conclusions

In China, NAFLD has become the most common form of liver disease, and it recognized as the second largest chronic liver disease [1518]. As a hepatic manifestation of the metabolic syndrome, we can suppose that NAFLD may promote the development of atherosclerosis [5, 6]. Some reports demonstrated that because of the promoting effect on CVD, NAFLD patients were at high risk of death [8, 10]. Nowadays many epidemiological and clinical studies focus on the association between NAFLD and CAD [1924]. Several studies have reported that NAFLD is a strong risk factor for CAD [25, 26]. A study demonstrates that NAFLD is an independent risk factor for angiographically in Koreans population, and also demonstrate that in Asians NAFLD can independently influence the progression to CAD [26].

AGTR1 is the receptor of Angiotensin II (AngII) [27], AngII as a potent vasopressor hormone and a main regulator of aldosterone secretion plays an important role in blood pressure control and also related to the pathogenesis of coronary diseases [11, 2831]. The main effect of AGTR1 is that can promote vascular contraction, regulating blood pressure and promoting aldosterone release [27]. Al-N et al. found that AGT rs2067853ˎrs699ˎ rs3789679ˎ rs2148582ˎ rs5051 polymorphisms could increase the risk for myocardial infarction [32].

Recently, people found that angiotensin II seemed to have a key character in the development of NASH [7]. They found that AngII acts on AGTR1 to activate hepatic stellate cells (HSCs), which could express the transforming growth factor-β1 (TGF-β1). TGF-β1 worked as a counter response to liver injury [33], While Z et al. found that AGTR1 gene rs3772622 was not associated with NAFLD and NASH [17]. This was in contrast with the Japanese study. Our studies found that AGTR1 gene rs3772622 was not associated with NAFLD in Chinese Han. The cause of the difference between different populations may be related to the factors such as race, environment and NAFLD diagnostic criteria. Angiotensin II type1 (AT1) receptors were divided into AT1a and AT1b two subtypes, and the distribution of subtype in liver tissue was racial difference. The distribution of AT1 subtype in Chinese population has not clear yet.

The current study is the first report to report that AGTR1 polymorphism increased the risk of NAFLD patients suffering from CAD. In this study we demonstrated that when compared with TC and TT genotype, the CC homozygote and carriers of C allele was significantly associated with NAFLD in patients with CAD, by comparing the risk between NAFLD patients with or without CAD, we found that there was a statistically significant difference in patients with CC genotype. then comparing the risk between without NAFLD people with or without CAD, we found that there still had statistically significant difference in people with CC genotype. However, by comparing the two OR values, AGTR1 rs3772622 polymorphisms can increase the risk of CAD in patients with NAFLD (OR1 > OR2).

NAFLD and CAD are both metabolic diseases, and study found that NAFLD is an independent risk factor for CAD. There must be a mechanism for the interaction between them.

However, our current study still has several limitations yet. We have the limitations on the studies of NAFLD spectrum, as we all know that the gold standard to diagnose NAFLD is liver biopsy, it can valid ascertainment and scoring of the different NAFLD stages. In clinical diagnosis, only limited application can we use liver biopsy technology. So it could not be widely used in the collection of specimens. Compared with the diagnosis of NASH, diagnosis of NAFLD can be based on radiological, clinical, and laboratory findings. Through these pathways above, it was more easily to collect the specimens of NAFLD patients. Ethics committee stipulated that it is not allow for biopsy in control group, thus no biopsies were applyed in controls. Strict criteria are required to reduce the likelihood of misclassifying in control group.

This final conclusion is that AGTR1 rs3772622 gene polymorphism was not associated with the risk of NAFLD, but could increase the risk of NAFLD patients suffering from CAD in the Chinese Han origin.

Declarations

Funding

This study was supported by Qingdao Livelihood, Science and Technology Project, China (Grant No.14-2-3-17-nsh) and Qingdao Key Health Discipline Development Fund.

Authors’ contributions

Study concept and design: YL, LL. Acquisition of data: LL, NG. Analysis and interpretation of data: YL, DY. Drafting of the manuscript: DY, NG. Critical revision of the manuscript for important intellectual content: YX. Statistical analysis: YL, LL. Administrative, technical, and material support: YX, SX. Study supervision: YX, SX. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Gastroenterology, Qingdao Municipal Hospital, School of Medicine, Qingdao University
(2)
Department of Gastroenterology, Qingdao Municipal Hospital
(3)
Digestive Disease Key Laboratory of Qingdao
(4)
Central Laboratories, Qingdao Municipal Hospital
(5)
Department of Anorecta, Qilu Hospital, of Shandong University

References

  1. Than NN, Newsome PN. Non-alcoholic fatty liver disease: when to intervene and with what. Clin Med. 2015;15:186–90.View ArticleGoogle Scholar
  2. MC J, Lynn Johnston B. Influenza - Expect the unexpected. Can J Infect Dis. 2004;15:13–6.View ArticleGoogle Scholar
  3. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525–40.View ArticlePubMedGoogle Scholar
  4. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–97.View ArticlePubMedGoogle Scholar
  5. Mehri S, Mahjoub S, Hammami S, Zaroui A, Frih A, Betbout F, Mechmeche R, et al. Renin-angiotensin system polymorphisms in relation to hypertension status and obesity in a Tunisian population. Mol Biol Rep. 2012;39:4059–65.View ArticlePubMedGoogle Scholar
  6. Ribeiro-Oliveira Jr A, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Silva AC S e. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag. 2008;4:787–803.PubMedPubMed CentralGoogle Scholar
  7. Zain SM, Mohamed Z, Mahadeva S, Rampal S, Basu RC, Cheah PL, Salim A, et al. Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population. PLoS ONE. 2013;8, e58538.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Sookoian S, Gianotti TF, Rosselli MS, Burgueno AL, Castano GO, Pirola CJ. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis. 2011;218:378–85.View ArticlePubMedGoogle Scholar
  9. Wang L, Hou L, Li H, Chen J, Kelly TN, Jaquish CE, Rao DC, et al. Genetic variants in the renin-angiotensin system and blood pressure reactions to the cold pressor test. J Hypertens. 2010;28:2422–8.PubMedPubMed CentralGoogle Scholar
  10. Zhang JA, Li JR, Qiao YJ. Association of AGTR1 gene A116C polymorphism with the risk of heart failure: a meta-analysis. Genet Mol Res. 2015;8:9163–70.View ArticleGoogle Scholar
  11. Kim HK, Lee H, Kwon JT, Kim HJ. A polymorphism in AGT and AGTR1 gene is associated with lead-related high blood pressure. J Renin Angiotensin Aldosterone Syst. 2014.Google Scholar
  12. Rickham PP. Human Experimentation. Code Of Ethics Of the World Medical Association. Declaration Of Helsinki. Br Med J. 1964;2:177.View ArticlePubMedGoogle Scholar
  13. Jian-gao F. Chinese Liver Disease A. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010;18:163–6.PubMedGoogle Scholar
  14. Cheng YH. A Novel Teaching-Learning-Based Optimization for Improved Mutagenic Primer Design in Mismatch PCR-RFLP SNP Genotyping. IEEE/ACM Trans Comput Biol Bioinform. 2016;13:86–98.View ArticlePubMedGoogle Scholar
  15. Chen GB, Xu Y, Xu HM, Li MD, Zhu J, Lou XY. Practical and theoretical considerations in study design for detecting gene-gene interactions using MDR and GMDR approaches. PLoS ONE. 2011;6:e16981.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Hu X, Feng F, Li X, Yuan P, Luan R, Yan J, et al. Gene polymorphisms related to insulin resistance and gene-environment interaction in colorectal cancer risk. Ann Hum Biol. 2015;1–9.Google Scholar
  17. Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, Iida H, et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int. 2009;29:1078–85.View ArticlePubMedGoogle Scholar
  18. Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, Bertolini L, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS ONE. 2015;10, e0135329.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Vilar CP, Cotrim HP, Florentino GS, Bragagnoli G, Schwingel PA, Barreto CP. Nonalcoholic fatty liver disease in patients with coronary disease from a Brazil northeast area. Arq Gastroenterol. 2015;52:111–6.View ArticlePubMedGoogle Scholar
  20. Vilar CP, Cotrim HP, Florentino GS, Barreto CP, Florentino AV, Bragagnoli G, Schwingel PA. Association between nonalcoholic fatty liver disease and coronary artery disease. Rev Assoc Med Bras. 2013;59:290–7.View ArticlePubMedGoogle Scholar
  21. Ampuero J, Gallego-Duran R, Romero-Gomez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig. 2015;107:10–6.PubMedGoogle Scholar
  22. Idilman IS, Akata D, Hazirolan T, Doganay Erdogan B, Aytemir K, Karcaaltincaba M. Nonalcoholic fatty liver disease is associated with significant coronary artery disease in type 2 diabetic patients: a computed tomography angiography study 2. J Diabetes. 2015;7:279–86.View ArticlePubMedGoogle Scholar
  23. Efe D, Aygun F. Assessment of the relationship between non-alcoholic fatty liver disease and CAD using MSCT. Arq Bras Cardiol. 2014;102:10–8.PubMedPubMed CentralGoogle Scholar
  24. Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Deepa M, Mohan V. Comparison of characteristics between nonobese and overweight/obese subjects with nonalcoholic fatty liver disease in a South Indian population. Diabetes Technol Ther. 2014;16:48–55.View ArticlePubMedGoogle Scholar
  25. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012;56:605–13.View ArticlePubMedGoogle Scholar
  26. Choi DH, Lee SJ, Kang CD, Park MO, Choi DW, Kim TS, Lee W, et al. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol. 2013;19:6453–7.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Pousada G, Baloira A, Valverde D. Molecular and clinical analysis of TRPC6 and AGTR1 genes in patients with pulmonary arterial hypertension. Orphanet J Rare Dis. 2015;10:1.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Palatini P, Ceolotto G, Dorigatti F, Mos L, Santonastaso M, Bratti P, Papparella I, et al. Angiotensin II type 1 receptor gene polymorphism predicts development of hypertension and metabolic syndrome. Am J Hypertens. 2009;22:208–14.View ArticlePubMedGoogle Scholar
  29. Nie SJ, Wen-ru T, Bi-feng C, Jin L, Wen Z, Sheng-jun L, Wei-wei L, et al. Haplotype-based case–control study of the human AGTR1 gene and essential hypertension in Han Chinese subjects. Clin Biochem. 2010;43:253–8.View ArticlePubMedGoogle Scholar
  30. Salminen LE, Schofield PR, Pierce KD, Conturo TE, Tate DF, Lane EM, Heaps JM, et al. Impact of the AGTR1 A1166C polymorphism on subcortical hyperintensities and cognition in healthy older adults. Age (Dordr). 2014;36:9664.View ArticleGoogle Scholar
  31. Valencia DM, Naranjo CA, Parra MV, Caro MA, Valencia AV, Jaramillo CJ, Bedoya G. Association and interaction of AGT, AGTR1, ACE, ADRB2, DRD1, ADD1, ADD2, ATP2B1, TBXA2R and PTGS2 genes on the risk of hypertension in Antioquian population. Biomedica. 2013;33:598–614.View ArticlePubMedGoogle Scholar
  32. Al-Najai M, Muiya P, Tahir AI, Elhawari S, Gueco D, Andres E, Mazhar N, et al. Association of the angiotensinogen gene polymorphism with atherosclerosis and its risk traits in the Saudi population. BMC Cardiovasc Disord. 2013;13:17.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Wereszczynka-Siemiatkowska U, Swidnicka-Siergiejko A, Siemiatkowski A, Bondyra Z, Wasielica-Berger J, Mroczko B, et al. Endothelin 1 and transforming growth factor-beta1 correlate with liver function and portal pressure in cirrhotic patients. Cytokine. 2015.Google Scholar

Copyright

© The Author(s). 2016

Advertisement